Replies to post #267947 on Avid Bioservices Inc (CDMO)

[Protector]

endoc, come on. Are you saying that AstraZeneca is going to run the Durvalumab+Bavituximab combo clinical trial, which is a immuno agent combination, in NSCLC just for the show. Because under your statement below that is all what is would be.

I was not hedging, but leaving open the small (small to the vanishing point) chance that Bavi could be used in combo with other immunology-oncology agents for advanced lung cancer.

Frowning eyebrows.